Dietrich Details Data and Future Research With Immunotherapy in Stage III NSCLC

Season 5 Episode 43  ·  Sep 20, 2021, 07:26 PM

Headliner
Share
Subscribe

Dr. Dietrich discusses the latest developments with immunotherapy and targeted therapy in stage III non–small cell lung cancer.

Share
Subscribe
Next
Monk Talks Tisotumab Vedotin and Exciting ESMO Data in Cervical Cancer
Top episodes
DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
by OncLive® On Air
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
by OncLive® On Air
Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
by OncLive® On Air